GlassScriptPhysician profile
Andrew P Kontos
NPI 1427164466
$3,149.81
in general payments reported to CMS, 2019-2025
21 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $763 · 2020: $179 · 2021: $303 · 2022: $272 · 2023: $441 · 2024: $725 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,473 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,472.51 |
| Education | $159.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $805.32 | 2019-2025 | |
| Merz North America, INC. | $638.48 | 2019-2024 | Xeomin |
| Janssen Biotech, INC. | $323.92 | 2020-2024 | Tremfya, Simponi Aria, Stelara |
| Mimedx Group, INC. | $221.22 | 2024-2025 | |
| Galderma Laboratories, L.P. | $189.01 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $147.89 | 2020-2025 | Blu-U |
| Ucb, INC. | $107.47 | 2022-2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.90 | 2022-2024 | Spevigo |
| Genentech USA, INC. | $91.67 | 2019-2024 | Erivedge |
| Amgen INC. | $78.23 | 2020-2022 | |
| Organogenesis INC. | $77.55 | 2023-2024 | Puraply |
| E.R. Squibb & Sons, L.L.C. | $72.39 | 2023-2024 | Sotyktu |
| Lilly USA, LLC | $53.45 | 2019-2021 | |
| Incyte Corporation | $50.88 | 2023 | Opzelura |
| Pfizer INC. | $47.03 | 2023-2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $43.84 | 2025 | |
| Misonix INC | $35.93 | 2020 | |
| Almirall LLC | $22.17 | 2022 | |
| Revance Therapeutics, INC. | $18.68 | 2024 | Daxxify |
| Dusa Pharmaceuticals, INC. | $16.92 | 2019 | |
| Leo Pharma INC. | $14.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Kontos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.